Trial record 1 of 1 for:    rHIgM22
Previous Study | Return to List | Next Study

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

This study is currently recruiting participants.
Verified March 2014 by Acorda Therapeutics
Sponsor:
Collaborator:
PRA International
Information provided by (Responsible Party):
Acorda Therapeutics
ClinicalTrials.gov Identifier:
NCT01803867
First received: February 26, 2013
Last updated: March 6, 2014
Last verified: March 2014

February 26, 2013
March 6, 2014
March 2013
July 2014   (final data collection date for primary outcome measure)
Safety and tolerability of single ascending doses of the human monoclonal rHIgM22 in patients with MS. [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
Monitoring of adverse events (AEs) will be conducted throughout the study. Adverse events, including serious adverse events will be recorded in the case report forms (CRFs).
Same as current
Complete list of historical versions of study NCT01803867 on ClinicalTrials.gov Archive Site
  • Measure the pharmacokinetics (PK) of single ascending doses of rHIgM22 [ Time Frame: Day 1 through Day 180 ] [ Designated as safety issue: No ]
    PK parameters will include; The maximum measured plasma concentration (Cmax), time to maximum plasma concentration (Tmax), half-life (T1/2), and the area under the concentration curve from time 0 to the concentration at last time point (AUC (0-last)).
  • Measure the pharmacodynamics of single ascending doses of rHIgM22 using the Expanded Disability Status Scale (EDSS) [ Time Frame: Day 1 through Day 180 ] [ Designated as safety issue: No ]
Measure the pharmacokinetics (PK) of single ascending doses of rHIgM22 [ Time Frame: Day 1 through Day 60± 7 ] [ Designated as safety issue: No ]
Serial blood samples will be collected from patients prior to and at specified times for up to 48 hours post treatment for PK assessments. PK parameters will include; The maximum measured plasma concentration (Cmax), time to maximum plasma concentration (Tmax), half-life (T1/2), and the area under the concentration curve from time 0 to the concentration at last time point (AUC (0-last)).
Not Provided
Not Provided
 
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)

This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Multiple Sclerosis
Drug: rHIgM22
Administered via IV infusion
Other Name: M22
Placebo Comparator: rHIgM22

Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.

Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD.

Intervention: Drug: rHIgM22
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
71
September 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Able to give written informed consent, with adequate cognitive function to sign the IRBapproved informed consent
  • Meet diagnostic criteria for MS, as defined by revised (2010) McDonald criteria
  • Man or woman aged 18 to 70 years, inclusive
  • Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and
  • Women of childbearing potential and engaged in heterosexual relations must agree to practice adequate contraception for at least 60 days after study dosing. Women of childbearing potential and not engaged in heterosexual relations or not practicing adequate contraception must agree to remain abstinent for at least 60 days after study dosing practice adequate contraception for the duration of the study
  • Agree to remain in the hospital for the 48 hour post infusion observation period, and can be contacted in case of an emergency once discharged

Exclusion Criteria:

  • Serum creatinine ≥1.5 mg/dL
  • Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or alkaline phosphatase ≥1.5 times the upper limit of normal
  • Angina, uncontrolled hypertension, clinically significant cardiac arrhythmias (including atrial fibrillation), any other clinically significant cardiovascular abnormality or clinically significant abnormal ECG
  • Immune-mediated disorder other than MS that in the Investigator's judgment, may affect the interpretation of results or the patient's ability to safely complete the study
  • Any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, allergic or anaphylactic reasons, or other major diseases (other than MS), that in the Investigator's judgment, may affect the interpretation of results or patient's ability to safely complete the study. This includes a suicide attempt within the past 1 year or severe suicidal ideation within the past 6 months or patients who in the opinion of the Investigator are at significant risk of suicidal behavior
  • MS relapse within 30 days prior to screening or treatment with systemic (oral, IV or IM) corticosteroids, except for minimally absorbed topical or inhalational preparations, within the 30 days prior to the Screening Visit
  • Initiation of interferon-beta 1b (Betaseron,a extavia), interferon beta-1a (Avonex, a Rebif a), glatiramer acetate (copaxone), natalizumab (Tysabri), or fingolimod (Gilenya), or dimethyl fumarate (Tecfidera ®) within the 90 days prior to the Screening Visit, or any change in the dosing regimen of these drugs within the 30 days prior to the Screening Visit. Initiation of teriflunomide (AUBAGIO®) or any change in the dosing regimen of this drug within 90 days prior to the Screening Visit.
  • Treatment with any of the following medications within the 12 months prior to Day 1 of the study: daclizumab, azathioprine, methotrexate, IV immunoglobulin, plasmaphoresis, or mycophenolate mofetil; or discontinuation of teriflunomide (AUBAGIO®) within 12 months prior to Day 1.
  • History of clinically significant infusion reactions with administration of biologics, including plasma exchange, intravenous immunoglobulin, and other monoclonal antibodies such as natalizumab (Tysabri)
  • Prior treatment with total lymphoid irradiation, T cell or T-cell receptor vaccination, alemtuzumab, mitoxantrone, cyclophosphamide, or rituximab
  • Received any investigational agent or therapy up to 30 days or 4 pharmacokinetic half-lives (whichever is longer) prior to Screening Visit or plans to enroll in another investigational trial at any time during this study
  • Contraindication to brain MRI or inability to tolerate brain MRI
Both
18 Years to 70 Years
No
Not Provided
United States
 
NCT01803867
IM22-MS-1004
Yes
Acorda Therapeutics
Acorda Therapeutics
PRA International
Study Director: Enrique Carrazana, MD Acorda Therapeutics
Acorda Therapeutics
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP